Has Ankit Anand, MD received payments from drug or device companies?

Yes. Drug and device makers reported $77,166 in general payments to Ankit Anand, MD across 218 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ankit Anand, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ankit Anand, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ankit Anand, MD

Hematology & Oncology · Farmington, NMNPI 1225383359

Payments from drug & device makers

$77,166in general payments, 2019–2025

Across 218 payments — averaging $353.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Astrazeneca UK Limited$61K
Bayer$7K
Exelixis Inc.$4K
Gilead$1K
Macrogenics, Inc.$1K
Novartis$316
plus $2K from 36 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Astrazeneca UK Limited	6	$61,069
Bayer	17	$6,902
Exelixis Inc.	21	$4,204
Gilead	16	$1,339
Macrogenics, Inc.	1	$1,083
Novartis	19	$316
Genentech USA, Inc.	13	$178
Merck	11	$176
E.r. Squibb & Sons, L.L.C.	16	$161
Johnson & Johnson	8	$152
Pfizer	6	$140
Amgen	8	$138
AstraZeneca(2 entities)	8	$132
Bristol Myers Squibb	7	$121
Astellas Pharma US Inc	6	$114
Takeda Pharmaceuticals U.S.A., Inc.	5	$85
Sanofi	4	$72
Puma Biotechnology, Inc.	5	$71
Seagen Inc.	4	$57
Eisai Inc.	3	$54
Verastem, Inc.	3	$49
Incyte Corporation	3	$48
Daiichi Sankyo Inc.	3	$44
Boehringer Ingelheim	2	$40
Spectrum Pharmaceuticals Inc.	2	$39
Lilly USA, LLC	2	$38
Roche Diagnostics Corporation	1	$36
Taiho Oncology, Inc.	2	$36
Rigel Pharmaceuticals, Inc.	2	$34
Recordati_rare_diseases_inc.	1	$29
Ipsen Biopharmaceuticals, Inc	2	$28
AVEO Pharmaceuticals, Inc.	1	$24
Tolmar Pharmaceuticals, Inc.	1	$21
Jazz Pharmaceuticals Inc.	1	$18
Array Biopharma Inc	1	$17
AbbVie	1	$16
Dova Pharmaceuticals	1	$16
Sun Pharmaceutical Industries Inc.	1	$16
Novocure Inc.	1	$15
Helsinn Therapeutics (U.S.), Inc.	1	$13
Lexicon Pharmaceuticals, Inc.	1	$13
EMD Serono, Inc.	1	$12

How this compares

$77,166 in reported general payments places this provider in the 60th percentile of 54 hematology & oncology providers in New Mexico.

See all hematology & oncology providers in New Mexico →

Medicare billing

Part B allowed, 2024

$1,812,837

Medicare patients

276

Services billed

78,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Farmington

Jeffrey NeidhartFarmington$1.5M
Sardar ImamFarmington$647K
James NeidhartFarmington$11
Ursa Brown GlabermanAlbuquerque$5M
Neda Hashemi SadraeiAlbuquerque$1.6M
Olivier RixeAlbuquerque$1.6M
Emrullah YilmazAlbuquerque$1.3M
Erika MaestasAlbuquerque$880K
Jose AvitiaAlbuquerque$553K
Jacklyn NemunaitisAlbuquerque$351K

See the full list for New Mexico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →